FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1981853586> ?p ?o ?g. }

• W1981853586 endingPage "613" @default.
• W1981853586 startingPage "608" @default.
• W1981853586 abstract "Patients with locally advanced or organ confined, high risk, prostate cancer are at significant risk of having disease recurrence despite definitive local therapy. We evaluated the 2-year progression-free survival of subjects treated with chemotherapy administered prior to definitive therapy with surgery or radiation.Patients (n = 24) with locally advanced and high risk localized prostate cancer were treated with neoadjuvant docetaxel 36 mg/m2 i.v. weekly for 3 weeks and estramustine 140 mg orally 3 times daily for 3 consecutive days every 28 days prior to definitive treatment with prostatectomy or radiation.All evaluable patients, except 1, completed the proposed cycles of neoadjuvant chemotherapy with minimal dose reductions or delays. Of the 22 evaluable patients, 12 underwent radical prostatectomy and 10 underwent external beam radiation therapy. Twenty-one of 22 patients achieved a prostate-specific antigen (PSA) reduction > 25%. There were no pathologic complete responses. With a median follow-up of 24 months, the 2-year progression-free survival was 45%.Our findings support the safety, tolerability, and efficacy of neoadjuvant chemotherapy in patients with men with high risk, locally advanced prostate adenocarcinoma, although the relative contributions of androgen deprivation therapy and docetaxel cannot be determined. The effectiveness of neoadjuvant chemotherapy in preventing prostate cancer relapses should be studied in a randomized trial." @default.
• W1981853586 created "2016-06-24" @default.
• W1981853586 creator A5002515600 @default.
• W1981853586 creator A5011907185 @default.
• W1981853586 creator A5012682914 @default.
• W1981853586 creator A5013954610 @default.
• W1981853586 creator A5016546709 @default.
• W1981853586 creator A5027261067 @default.
• W1981853586 creator A5062111389 @default.
• W1981853586 creator A5073387299 @default.
• W1981853586 creator A5075863856 @default.
• W1981853586 creator A5082025794 @default.
• W1981853586 creator A5086661060 @default.
• W1981853586 date "2011-11-01" @default.
• W1981853586 modified "2023-10-01" @default.
• W1981853586 title "Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: A phase II trial" @default.
• W1981853586 cites W1496645825 @default.
• W1981853586 cites W1967324977 @default.
• W1981853586 cites W1967770117 @default.
• W1981853586 cites W1970316517 @default.
• W1981853586 cites W1973089211 @default.
• W1981853586 cites W2000979583 @default.
• W1981853586 cites W2015309327 @default.
• W1981853586 cites W2021220421 @default.
• W1981853586 cites W2025928627 @default.
• W1981853586 cites W2028469204 @default.
• W1981853586 cites W2031663842 @default.
• W1981853586 cites W2037610329 @default.
• W1981853586 cites W2043103956 @default.
• W1981853586 cites W2080439368 @default.
• W1981853586 cites W2087274845 @default.
• W1981853586 cites W2094616039 @default.
• W1981853586 cites W2094804958 @default.
• W1981853586 cites W2117792530 @default.
• W1981853586 cites W2120292596 @default.
• W1981853586 cites W2134766389 @default.
• W1981853586 cites W2135312889 @default.
• W1981853586 cites W2144498681 @default.
• W1981853586 cites W2150909545 @default.
• W1981853586 cites W2156569873 @default.
• W1981853586 cites W2242179439 @default.
• W1981853586 cites W2316095838 @default.
• W1981853586 cites W4321059479 @default.
• W1981853586 doi "https://doi.org/10.1016/j.urolonc.2009.09.012" @default.
• W1981853586 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20022268" @default.
• W1981853586 hasPublicationYear "2011" @default.
• W1981853586 type Work @default.
• W1981853586 sameAs 1981853586 @default.
• W1981853586 citedByCount "18" @default.
• W1981853586 countsByYear W19818535862012 @default.
• W1981853586 countsByYear W19818535862013 @default.
• W1981853586 countsByYear W19818535862014 @default.
• W1981853586 countsByYear W19818535862015 @default.
• W1981853586 countsByYear W19818535862016 @default.
• W1981853586 countsByYear W19818535862017 @default.
• W1981853586 countsByYear W19818535862018 @default.
• W1981853586 countsByYear W19818535862022 @default.
• W1981853586 countsByYear W19818535862023 @default.
• W1981853586 crossrefType "journal-article" @default.
• W1981853586 hasAuthorship W1981853586A5002515600 @default.
• W1981853586 hasAuthorship W1981853586A5011907185 @default.
• W1981853586 hasAuthorship W1981853586A5012682914 @default.
• W1981853586 hasAuthorship W1981853586A5013954610 @default.
• W1981853586 hasAuthorship W1981853586A5016546709 @default.
• W1981853586 hasAuthorship W1981853586A5027261067 @default.
• W1981853586 hasAuthorship W1981853586A5062111389 @default.
• W1981853586 hasAuthorship W1981853586A5073387299 @default.
• W1981853586 hasAuthorship W1981853586A5075863856 @default.
• W1981853586 hasAuthorship W1981853586A5082025794 @default.
• W1981853586 hasAuthorship W1981853586A5086661060 @default.
• W1981853586 hasConcept C121608353 @default.
• W1981853586 hasConcept C126322002 @default.
• W1981853586 hasConcept C126894567 @default.
• W1981853586 hasConcept C141071460 @default.
• W1981853586 hasConcept C143998085 @default.
• W1981853586 hasConcept C197934379 @default.
• W1981853586 hasConcept C2776235491 @default.
• W1981853586 hasConcept C2776694085 @default.
• W1981853586 hasConcept C2777899217 @default.
• W1981853586 hasConcept C2778375690 @default.
• W1981853586 hasConcept C2779466945 @default.
• W1981853586 hasConcept C2780192828 @default.
• W1981853586 hasConcept C2780201970 @default.
• W1981853586 hasConcept C2781190966 @default.
• W1981853586 hasConcept C2781406297 @default.
• W1981853586 hasConcept C2994223898 @default.
• W1981853586 hasConcept C509974204 @default.
• W1981853586 hasConcept C71924100 @default.
• W1981853586 hasConceptScore W1981853586C121608353 @default.
• W1981853586 hasConceptScore W1981853586C126322002 @default.
• W1981853586 hasConceptScore W1981853586C126894567 @default.
• W1981853586 hasConceptScore W1981853586C141071460 @default.
• W1981853586 hasConceptScore W1981853586C143998085 @default.
• W1981853586 hasConceptScore W1981853586C197934379 @default.
• W1981853586 hasConceptScore W1981853586C2776235491 @default.
• W1981853586 hasConceptScore W1981853586C2776694085 @default.
• W1981853586 hasConceptScore W1981853586C2777899217 @default.
• W1981853586 hasConceptScore W1981853586C2778375690 @default.

• next